Adaptive dose-finding studies: a review of model-guided phase I clinical trials. - Wikidata - wikimedia - TriplyDB

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

http://www.wikidata.org/entity/Q34001009

about

Phase I trials of antitumour agents: fundamental concepts Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials Approaches to modernize the combination drug development paradigm Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.Performance of toxicity probability interval based designs in contrast to the continual reassessment method.Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.Implementation of adaptive methods in early-phase clinical trials.A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update Statistics in clinical research: Important considerations Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Embracing model-based designs for dose-finding trials.Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.Monoclonal antibodies for treating gastric cancer: promises and pitfalls.Nucleoside analogs: ready to enter the era of precision medicine?Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan Response-adaptive clinical trials: case studies in the medical literature.Conditional estimation in two-stage adaptive designs.Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?A web application for evaluating Phase I methods using a non-parametric optimal benchmark.Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.WNT signalling in prostate cancer.A web tool for designing and conducting phase I trials using the continual reassessment method Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.Integrating genomic information and signaling dynamics for efficient cancer therapy.Revisiting isotonic phase I design in the era of model-assisted dose-finding

P2860

Q26865346-7A586206-5BCF-4B9F-BD58-A6B7946D0ECA Q27023178-D0D07832-5495-47F2-8E16-F41BBAAC3269 Q28072074-8E566ED9-81D2-4976-B71A-66D608C2426C Q30275159-915FF669-6511-43C1-A4A1-DCBE2084F960 Q30276332-5DE97C16-05A9-436E-ADA1-51AD68193E78 Q30276967-4A39D0FD-E6D2-4D6E-897E-1075869C4542 Q30277243-136CC658-CA51-4553-BFC9-3F9A984BCBF9 Q30300873-AA180581-673B-4A43-B94A-A7B067F8CB65 Q33434352-BEED1C7B-5837-4B63-AB6F-7D474F2064EC Q35894574-A46448C4-B9CE-45E6-B915-93AD248CB460 Q35904534-6A53E36C-4975-4D0E-849A-72D1EF33E62A Q36987761-52B7DBB2-903C-4B38-87DC-B47608AD1264 Q37129865-A1B80BA8-8BBE-4ADF-9C13-75E87D29170F Q37624593-E001E1A8-079F-4CED-BE62-C4FAA2B6CE1C Q38700689-479BBD77-4155-45A2-BEE6-4AE3BB278AC2 Q38735952-84186928-8662-44AC-A133-4A4CABC69C58 Q38767329-F9639CEF-6A92-4D65-B633-4638EEECFD3F Q38772049-87C33461-81AE-4BE2-8EE6-ADBFCC9A9D97 Q38842938-D5CBB209-13E9-45D1-8E6A-D5A23B2FC003 Q38907890-CA6DC4CB-694E-488F-9911-54C4D49ED06A Q39300281-06FE7A23-E875-4891-B831-84379C83EFB3 Q40375028-C0792B9B-F163-4F41-A36C-2DAFAB06BDDD Q41282610-95589742-B7E1-4D6D-8476-C46085E419FE Q42363788-B926FAB2-00CA-4C11-9B3C-1DC27ABA4819 Q45062066-F4D2C6FE-56FA-4145-BE3A-886F559CFC9A Q45063894-3157DBBB-8622-4412-B449-AC485163E525 Q45952214-83C8D588-2389-4282-A540-D91B968F1369 Q46036046-E622E7AF-9405-45FC-9B4A-A44E20CAEC3F Q47732625-CF60E264-1A1F-4429-9E85-A7895320AD01 Q47818549-ED83573E-A75A-484F-8F30-011B93EE5353 Q49766564-7A986334-D1BC-407E-91B1-A9912ADE4E0D Q53265989-DE36F141-192D-4DAB-81F4-D536A868E69B Q53522981-2FE79664-568F-4C08-88C8-0AC0860285B7 Q54983582-BE8D882A-4F9E-4129-AACB-DC7CE819B0D3 Q56334300-FA2E21A8-2234-4D14-8891-8C0CAB41AAA3

P2860

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

http://www.wikidata.org/entity/Q34001009

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@ast

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@en

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@nl

type

label

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@ast

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@en

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@nl

prefLabel

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@ast

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@en

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@nl

P1433

Q34001009-D9E1E414-81B3-474C-8EB6-AEC843913E2D

P1476

Q34001009-2AB28E2B-AC9E-4ACD-BA8A-B1FFF2CE7850

P2093

Q34001009-2B0CD047-BE1F-4984-8FCD-DD4716BAF4CA

Q34001009-CC48F251-A34F-4968-ABD7-83C6CFE34CD8

P2860

Q34001009-00CA21E1-9A73-4323-A8EF-316684D2D7E5

Q34001009-01AC8832-F3EB-41D3-B07A-8242C3F2901C

Q34001009-01C52479-DF06-4A0D-BA6E-7500B83AE93D

Q34001009-04F35D95-940A-45D3-9AD2-A82EB677FA10

Q34001009-0574F824-5B46-4CB6-A194-6E475843E822

Q34001009-05894A3D-5413-408E-9B89-5E9288676BA4

Q34001009-09C5F1C1-E0F3-4297-BC50-263B148B2987

Q34001009-13021C49-C6CE-4841-BC19-D72BDB350EC4

Q34001009-18480EFD-83D7-4C8B-84D1-5C7EFFEF63F4

Q34001009-1A3DC578-3442-4D3D-8CB7-A80E5716E933

P304

Q34001009-761606ED-1352-4172-BEC8-B715FF394227

P31

Q34001009-E8129EC0-ABF1-4425-91D2-9D9004ABB50C

P356

Q34001009-B097CACB-CF3D-43B9-B4D7-2951D01979AE

P407

Q34001009-2F97873A-4EB6-404E-A250-0FA159ED32B1

P433

Q34001009-E5A45D7C-1F75-4E1C-9A50-C8A96A69C5DF

P478

Q34001009-E880C615-FE46-4F10-800A-17103D652A3B

P577

Q34001009-EAA6677C-8ADE-4544-953B-47B7EA5736A0

P698

Q34001009-E1D59DE8-330E-4331-A2F7-CF40E753C25B

P921

Q34001009-4E050AA5-A3D8-4874-A73E-E261ED889F8F

P932

Q34001009-B868DE71-1D00-4C59-AE48-FCBD7496A89B

P356

JCO.2013.54.6051

P1433

Journal of Clinical Oncology

P1476

Adaptive dose-finding studies: a review of model-guided phase I clinical trials.

@en

P2093

Alexia Iasonos

http://www.w3.org/2001/XMLSchema#string

John O'Quigley

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

Continual reassessment method for partial ordering.

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.

Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

P304

2505-2511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.54.6051

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24982451

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4121508

http://www.w3.org/2001/XMLSchema#string